Voices
Miguel Martín։ SET ER/PR Index Predicts Benefit from Weekly Adjuvant Paclitaxel
Miguel Martín/LinkedIn

Miguel Martín։ SET ER/PR Index Predicts Benefit from Weekly Adjuvant Paclitaxel

Miguel Martín, Emeritus Professor of Medicine at Universidad Complutense, Madrid, shared on LinkedIn:

“This GEICAM study suggests that low endocrine transcriptional activity measured by the SET ER/PR index can predict which chemotherapy regimen would offer survival benefit for an individual patient. SET ER/PR index is the first genomic assay that seems able to o predict benefit from taxane-based chemotherapy.”

Title: Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial

Authors: Miguel Martín, Alvaro Rodriguez-Lescure, Cristina Reboredo, Eveline Chen, Manuel Ruiz-Borrego, Ana Santaballa Bertran, Cesar A. Rodríguez, Noelia Martinez-Jañez, Emilio Alba, Kevin Tran, Ignacio Pelaez Fernandez, Isabel Álvarez, Miguel A. Seguí, Alberto de la Cruz, Vicente Valero, Antonio Antón-Torres, Raquel Andrés, Kepa Amillano, José J. Ponce-Lorenzo, Severina Dominguez Fernandez, Jesus Herranz, Raul Rincon, Rosalía Caballero, Angel Guerrero-Zotano, Federico Rojo, W. Fraser Symmans

Read the article

Other articles about on OncoDaily.

Alberto de la Cruz Álvaro Rodríguez-Lescure Ana Santaballa Bertran Angel Guerrero-Zotano Antonio Antón-Torres cancer César A. Rodríguez Cristina Reboredo Emilio Alba Eveline Chen Federico Rojo Ignacio Pelaez Fernandez Isabel Álvarez Jesús Herranz José J. Ponce-Lorenzo Kepa Amillano Kevin Tran Manuel Ruiz Borrego Miguel A. Seguí Miguel Martin Noelia Martínez Jañez OncoDaily Oncology Paclitaxel Raquel Andrés Raul Rincon Rosalía Caballero Severina Dominguez Fernandez Vicente Valero W. Fraser Symmans